RxDoctor Payments DataLook up a doctor →

Veryl Hodges, DO

Internal Medicine · Jonesboro, ARNPI 1013903269

Payments from drug & device makers

$8,149in general payments, 2019–2025

Across 622 payments — averaging $13.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$884
  • AstraZeneca$780
  • Pfizer$769
  • Johnson & Johnson$680
  • Astellas Pharma US Inc$512
  • Amgen$477
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$8,06199%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,149 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$126,076
Medicare patients
350
Services billed
7,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$102,116
OzempicSemaglutide52$52,656
JardianceEmpagliflozin41$36,633
XareltoRivaroxaban52$33,079
MounjaroTirzepatide20$30,924
FarxigaDapagliflozin Propanediol47$29,289
JanuviaSitagliptin Phosphate30$27,097
MyrbetriqMirabegron18$24,264
LinzessLinaclotide37$20,642
Breo ElliptaFluticasone/Vilanterol23$10,995
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$10,619
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$9,427
Tresiba Flextouch U-100Insulin Degludec13$6,035
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,910
Duloxetine Hcl172$3,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$769$102,116118 claims
Novo NordiskOzempic$364$52,65652 claims
Boehringer IngelheimJardiance$323$36,63341 claims
Johnson & JohnsonXarelto$680$33,07952 claims
Lilly USA, LLCMounjaro$207$30,92420 claims
AstraZenecaFarxiga$780$29,28947 claims
MerckJanuvia$228$27,09730 claims
Astellas Pharma US IncMyrbetriq$512$24,26418 claims
AbbVieLinzess, Synthroid$884$22,34651 claims
GSKBreo Ellipta, Anoro Ellipta$440$16,90635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →